Rapid Micro Biosystems (RPID) Debt Ratio (2020 - 2026)

Rapid Micro Biosystems (RPID) reported Debt Ratio of 0.31 for Q1 2026, up 20.99% sequentially from 0.25 in Q4 2025.

Rapid Micro Biosystems (RPID) Debt Ratio (2020 - 2026) Analysis & Trends

Rapid Micro Biosystems (RPID) has 4 years of Debt Ratio data on file, last reported at 0.31 in Q1 2026.

For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.31; the trailing twelve-month figure through Mar 2026 stood at 0.31 (changed N/A YoY), and the FY2025 full-year result was 0.25, changed N/A from the prior year.
Debt Ratio advanced to 0.31 in Q1 2026, from 0.25 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.31 in Q1 2026 to a low of 0.22 in Q3 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	0.31
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	0.32
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	0.30
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	0.04
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	0.30
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	0.27
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	0.30
10	Rapid Micro Biosystems	90.41 Mn	80.98 Mn	371,000.00	0.31

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.31
Dec 31, 2025	0.25
Sep 30, 2025	0.22
Jun 30, 2021	0.19
Dec 31, 2020	0.35